- Home
- CMRE vs XERS Comparison
CMRE vs XERS Comparison
Compare CMRE & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMRE | XERS |
|---|---|---|
| Founded | 1974 | 2005 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CMRE | XERS |
|---|---|---|
| Price | $15.05 | $9.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $20.00 | $12.29 |
| AVG Volume (30 Days) | 292.7K | ★ 1.9M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.40% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | N/A | $32.77 |
| Revenue Next Year | N/A | $24.06 |
| P/E Ratio | $5.55 | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $10.84 | $5.25 |
| 52 Week High | $18.06 | $10.09 |
Technical Indicators
Market Signals| Indicator | CMRE | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 67.03 |
| Support Level | $13.86 | $7.15 |
| Resistance Level | $15.79 | N/A |
| Average True Range (ATR) | 0.35 | 0.46 |
| MACD | -0.05 | 0.18 |
| Stochastic Oscillator | 20.00 | 85.23 |
Price Performance
Historical ComparisonAbout CMRE Costamare Inc. $0.0001 par value
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and others. The company provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.